NeoGenomics, Inc. (NEO) Stock Analysis
Last updated Oct 27, 2026
Health Check
Last analyzed Oct 23, 2026
- Financial Health 30
- Profitability 40
- Business Quality 60
- Balance Sheet 30
- Cash Flow 35
Why this rating?
Health 39/100 — Avoid
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
NeoGenomics, Inc. (NEO) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates NeoGenomics, Inc. 39/100 (Avoid) due to solid business quality, steady revenue growth, and elevated leverage.
Investment profile
- Quality Moderate
- Growth Moderate
- Balance Sheet Stretched
- Valuation Elevated
Financial highlights
Valuation
- Forward P/E 50.39
- PEG 2.09
- EV/Revenue 3.19
Profitability
- Revenue Growth 11.2%
- Gross Margin 43.9%
- Operating Margin -4.8%
- Net Margin -6.8%
- ROE -6.3%
Financial strength
- Cash $145.54M
- Debt $448.37M
- Net Cash $-302.83M
- Free Cash Flow $-21.78M
- Current Ratio 3.6
Similar companies
Peers in Diagnostics & Research, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Veracyte, Inc. Diagnostics & Research VCYT$50.28 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Good Entry Good EntryA usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
- Illumina, Inc. Diagnostics & Research ILMN$279.47 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- CareDx, Inc. Diagnostics & Research CDNA$70.53 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Qiagen N.V. Diagnostics & Research QGEN$50.17 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Danaher Corporation Diagnostics & Research DHR$232.00 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Quest Diagnostics Incorporated Diagnostics & Research DGX$242.56 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Sotera Health Company Diagnostics & Research SHC$18.49 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Revvity, Inc. Diagnostics & Research RVTY$161.86 66 Health 66 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks NeoGenomics, Inc. (NEO).